WALTHAM, Mass., Oct. 17 /PRNewswire/ -- Epitome Biosystems announced today the receipt of a Phase II SBIR grant from the National Science Foundation. The Company will use the grant of $500,000 over two years to develop an antibody array that will integrate the measurement of phosphoproteins from three important cell signaling pathways into a single assay system. Upon successful completion of the development program, Epitome intends to market the resulting product to the research community, either directly or through a distribution partner.
Epitome's EpiTag(TM) technology enables the identification of unique amino acid sequences or "tags" within a protein. Antibodies raised against these peptides tags, rather than the entire protein, have predetermined specificity and high affinity and can precisely target specific regions of phosphorylation within the protein. The EpiTag assay harnesses the power of these antibodies by measuring peptide fragments, released from the protein by digestion, rather than the entire protein. By reducing the measurement system to a peptide level, Epitome provides a universal, efficient and scalable method for developing and conducting multiplex protein assays.
Neal Gordon, Ph.D., President of Epitome stated, "the SBIR Phase II award not only provides a source of development funding but also represents an important endorsement of our technology platform. We expect to deliver a compelling new measurement tool for scientists studying cell signaling pathways that play critical roles in cancer and other diseases."
In May 2004, Epitome Biosystems was awarded Phase I of the SBIR grant to demonstrate feasibility of the EpiTag technology platform for phosphoprotein analysis. During the Phase I project, the company developed highly specific and high affinity antibodies for peptide tags identified for proteins in the MapK signaling pathway and used the antibodies in an array format for multiplex measurement of protein phosphorylation. The recent award will enable Epitome Biosystems to develop commercial products with expanded array content that encompass three cell signaling pathways.
About Epitome Biosystems
Epitome Biosystems is a pioneer in the development of a new breed of protein measurement tools. Its proprietary EpiTag(TM) technology delivers highly specific antibodies and assay standards for quantitation of any protein based solely on sequence. These reagents easily interface with any measurement system including bead based and planar array platforms and are particularly useful in developing micro-scale immunoassays. Epitome Biosystems is backed by funding from Flagship Ventures and Vinod Khosla, with offices in Waltham, MA. For more information, visit www.epitomebiosystems.com.
CONTACT: Neal F. Gordon, Ph.D. of Epitome Biosystems, +1-781-209-2370,email@example.com